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ernakalant
dditional Evidence
or Safety and Efficacy for
ew Onset Atrial Fibrillation*
ruce D. Lindsay, MD
leveland, Ohio
trial fibrillation (AF) afflicts approximately 1% to 1.5% of
he developed world and 2.3 million Americans. It is the
ost common arrhythmia requiring treatment in the emer-
ency department and admission to the hospital. It con-
umes 1% of the health care budget in the United Kingdom
nd France and $6.65 billion in the U.S. (1–4). Yet, the
umber of drugs available to treat AF is modest, and they
ave limited efficacy and are associated with a number of
dverse effects. We need more effective drugs with optimal
afety profiles for rapid conversion of new-onset AF. One
romising new drug is vernakalant, which is a novel anti-
rrhythmic drug that blocks early activating K channels
IKur) and frequency-dependent Na
 channels. It is rela-
ively atrial selective because the density of IKur channels is
igher in the atria and the effects on sodium channels are
ate dependent (5). Accordingly, these effects are more
ronounced in the fibrillating atria than the ventricles.
ernakalant has undergone several clinical trials and is
nder consideration for approval by the Food and Drug
dministration (FDA).
See page 313
In this issue of the Journal, Camm et al. (6) reported the
esults of the AVRO trial, which was a multicenter, ran-
omized, blinded phase III clinical study comparing the
nvestigational drug vernakalant with amiodarone for con-
ersion of new-onset AF 3 h but 7 days in duration. As
ith most investigations, many subsets of patients who have
F were excluded. The exclusion criteria included those
ith acute decompensated heart failure or coronary syn-
romes, hypertrophic cardiomyopathy, history of ventricular
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio. The Cleveland Clinic Foundation receives fellowship support from
iosense Webster, Medtronic, Boston Scientific, and St. Jude Medical. Dr. Lindsayc
as received speaker honoraria from Medtronic, and has served as a consultant to
oisense Webster, Cardioinsight, and Siemens.rrhythmias, or baseline QT intervals 440 ms. Nonethe-
ess, structural heart disease was present in 35% of those
nrolled; therefore, it is representative of many patients who
re seen with new-onset AF.
The AVRO investigators showed a conversion rate of
2% within 90 min when vernakalant was administered
ompared with 5% for amiodarone (6). The median time to
onversion was 11 min in the vernakalant arm. Few patients
ho received vernakalant relapsed back into AF. Although
miodarone helps to control the rate when patients are in
F, the overall relief of symptoms was greater with ver-
akalant. Interestingly, 8.6% converted from AF to atrial
utter in the vernakalant arm. Perhaps this risk would be
reater for patients excluded from the study who might have
ore extensive atrial disease and other comorbidities, but it
ccurred in a setting where it could be easily managed by
ardioversion. I do not view this observation as a cause for
oncern, but it is a potential outcome that must be consid-
red when vernakalant is administered and could have
mplications for the oral formulation.
The trial report by Camm et al. (6) differed from the
CT I (Atrial Arrhythmia Conversion Trial I), which
ompared vernakalant with placebo as opposed to another
ctive drug in patients with AF or atrial flutter. The results
f the 2 trials showed similar safety and efficacy for
ernakalant. ACT I enrolled 416 patients to evaluate the
afety and efficacy of vernakalant compared with placebo. In
his study, the conversion rate for new-onset AF 3 h and
7 days was 52% for vernakalant and 4% for placebo.
ernakalant was not effective for converting atrial flutter (7).
CT II was another trial in which vernakalant was admin-
stered to patients with new-onset AF or atrial flutter
ollowing coronary artery bypass graft or valve replacement
urgery. The conversion rate was 47% within 90 min for AF
ompared with a conversion rate of 14% for placebo (8).
One may question why amiodarone was selected as the
omparison drug when other studies have shown that
miodarone has low efficacy for conversion of AF. In
ractice, intravenous amiodarone is used extensively in the
mergency department, telemetry floors, and intensive care
nits. My impression is that amiodarone is used either
ecause it helps to control the ventricular rate or because of
he misperception that it is effective in converting AF to
inus rhythm. Given these realities, the decision to compare
ernakalant with amiodarone seems very relevant.
Why not compare vernakalant with a drug such as
butilide, which is administered intravenously and targeted
oward patients with new-onset AF and atrial flutter? One
ractical constraint is that ibutilide is not available in some
uropean countries, just as intravenous formulations of
ecainide and propafenone are not available in the U.S.
here are significant differences between ibutilide and
ernakalant. Ibutilide prolongs repolarization by blocking
he rapid component of the delayed rectifier potassium
urrent in both the atria and the ventricles and is available
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January 18, 2011:322–3 Vernakalant: Safety and Efficacynly as an intravenous formulation. It is difficult to compare
he efficacy of ibutilide with that of vernakalant because of
ignificant differences in the clinical trials. The majority of
he patients in 2 important ibutilide trials had structural
eart disease, a significant number had left atrial enlarge-
ent, and there was a broad range in the duration of AF.
lthough the efficacy for conversion of AF is reported to be
n the range of 30%, it may be higher in AF of very short
uration (9,10). There are 2 significant differences in the
ffects of these drugs. Vernakalant is relatively atrial selec-
ive and appears to have a low incidence of inducing
entricular arrhythmias. It has low efficacy for conversion of
trial flutter. In contrast, the efficacy of ibutilide for con-
ersion of atrial flutter is reportedly 38% to 63% (9,10). The
isk of inducing polymorphic ventricular tachycardia follow-
ng administration of ibutilide is in the range of 4% to 8%.
hese characteristics could influence the choice of which
rug to use; however, a randomized trial is needed to
ompare the safety and efficacy of ibutilide and vernakalant
or conversion of new-onset AF.
Vernakalant remains an investigational drug. In 2007, an
dvisory panel recommended approval, but the FDA re-
uested additional safety data because of concerns related to
he risk of hypotension and usage in patients with heart
ailure or acute coronary syndromes. Results from the
ernakalant trials have shown potentially drug-related seri-
us adverse events in approximately 2%, but it does not
ppear to be associated with an appreciable risk of torsades
e pointes or sustained ventricular arrhythmias. The rela-
ively high conversion rate for new-onset AF would facili-
ate treatment of patients in the emergency department and
ould reduce cost of care if patients could be discharged with
ollow-up in the office as opposed to the need for admission
o the hospital. Although results from these trials are
ncouraging and may lead to approval by the FDA, caution
hould be exercised if the drug is administered to patients cith more extensive heart disease or comorbidities who
ere excluded from these studies.
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